<DOC>
	<DOCNO>NCT00468351</DOCNO>
	<brief_summary>Intravitreal triamcinolone effective central macular thickness reduction concomitant visual acuity improvement patient diabetic macular edema ( DME ) . VEGF effective inducer permeability , 50.000 time potent histamine , may exert effect retinal vascular permeability alter tight-junctions protein , occlude VE-cadherin . Based principle , rationale anti-VEGF agent treatment increase retinal capillary permeability condition , diabetic macular edema . Therefore , conduct randomize , prospective study compare efficacy safety intravitreal triamcinolone acetonide intravitreal bevacizumab injection refractory diffuse DME .</brief_summary>
	<brief_title>Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab Refractory Diabetic Macular Edema ( IBEME Study )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Refractory diffuse DME ( define herein clinically significant DME [ biomicroscopic evaluation ] unresponsive focal laser photocoagulation [ perform least 3 month evaluation ] generalize breakdown inner bloodretina barrier diffuse fluorescein leakage involve foveal center macular area fluorescein angiography ) , Snellen logarithm minimum angle resolution ( LogMAR ) BCVA equivalent 20/40 worse , 3 ) central macular thickness ( CMT ) great 300Âµm optical coherence tomography ( OCT ) Aphakic pseudophakic eye , Glycosylated hemoglobin ( Hb A1C ) rate 10 % , History glaucoma ocular hypertension , Loss vision result cause , Systemic corticoid therapy , . History thromboembolic event ( include myocardial infarction cerebral vascular accident ) ; Major surgery within prior 6 month plan within next 28 day ; Uncontrolled hypertension ( accord guideline seventh report joint National Committee Prevention , Detection , Evaluation , Treatment High Blood Pressure [ JNC7 ] ) ; 16 Known coagulation abnormality current use anticoagulative medication aspirin ; Severe systemic disease ; Any condition affect followup documentation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>diabetes</keyword>
	<keyword>intravitreal</keyword>
	<keyword>macular edema</keyword>
	<keyword>triamcinolone</keyword>
	<keyword>VEGF</keyword>
</DOC>